Compare EMBC & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | FOCL |
|---|---|---|
| Founded | 1924 | N/A |
| Country | United States | France |
| Employees | N/A | 289 |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 203.7M |
| IPO Year | 2021 | N/A |
| Metric | EMBC | FOCL |
|---|---|---|
| Price | $3.37 | $5.68 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 44.1K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 6.88% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $4.76 |
| 52 Week High | $15.55 | $5.64 |
| Indicator | EMBC | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 87.94 |
| Support Level | $3.03 | $5.30 |
| Resistance Level | $3.48 | N/A |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 66.27 | 100.00 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.